Click on a filter below to refine your search. Remove a filter to broaden your search.
Findings seen over three years in adults with preexisting cardiovascular disease and overweight or obesity
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
A significant reduction was seen in systolic blood pressure with zilebesiran 150, 300 or 600 mg once in six months and 300 mg once every three months.
Patients receiving mental health treatment were less likely to be rehospitalized, have an emergency department visit or die from any cause.
One-third of those say their lives were disrupted by the overdose death.
Nurse practitioners were overrepresented among clinicians with the highest and lowest rates of inappropriate prescribing.
Dapagliflozin, however, does not reduce the urinary albumin-to-creatinine ratio in those patients.
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
The GA enlargement rate in the study eyes did not differ significantly in the run-in and treatment phases in age-related macular degeneration.
Baseline CRP, Clinical Disease Activity Index and glucocorticoid dose predict resistance to CDAI-low disease activity achievement.